### Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>482</td>
<td>Hepatitis E in immunocompromised individuals</td>
<td>Damiris K, Aghaie Meybodi M, Niazi M, Pyrsopoulos N</td>
</tr>
<tr>
<td>495</td>
<td>Small duct primary sclerosing cholangitis: A discrete variant or a bridge to large duct disease, a practical review</td>
<td>Nguyen CM, Kline KT, Stevenson HL, Khan K, Parupudi S</td>
</tr>
<tr>
<td>504</td>
<td>New progress in understanding roles of nitric oxide during hepatic ischemia-reperfusion injury</td>
<td>Zhang YP, Liu XR, Yang MW, Yang SL, Hong FF</td>
</tr>
<tr>
<td>525</td>
<td>Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review</td>
<td>Spera AM</td>
</tr>
<tr>
<td>535</td>
<td>Fertaric acid amends bisphenol A-induced toxicity, DNA breakdown, and histopathological changes in the liver, kidney, and testis</td>
<td>Koriem KMM</td>
</tr>
<tr>
<td>551</td>
<td>Prevalence of hypothyroidism and effect of thyroid hormone replacement therapy in patients with non-alcoholic fatty liver disease: A population-based study</td>
<td>Almomani A, Hitawala AA, Kumar P, Alquaisi S, Alshaikh D, Alkhayyat M, Asaad I</td>
</tr>
<tr>
<td>559</td>
<td>Standards of liver cirrhosis care in Central Australia</td>
<td>Raja SS, Batey RG, Edwards S, Aung HH</td>
</tr>
<tr>
<td>570</td>
<td>Risk factors and prediction of acute kidney injury after liver transplantation: Logistic regression and artificial neural network approaches</td>
<td>Bredt LC, Peres LAB, Risso M, Barros LCAL</td>
</tr>
</tbody>
</table>
Contents

Retrospective Study
583 Pediatric liver transplantation outcomes from a single center in Thailand

Observational Study
592 Predictors of Mortality at 28-days in Infection associated Acute Kidney Injury in Cirrhosis
Gupta T, Ranga N, Goyal SK

602 Benign course of residual inflammation at end of treatment of liver transplant recipients after sofosbuvir based therapy
Ismail B, Benrajab KM, Bejarano P, Ruiz P, Sears D, Tzakis A, Zervos XB

612 Interrelationship between physical activity and depression in nonalcoholic fatty liver disease
Weinstein AA, De Avila L, Kannan S, Paik JM, Golabi P, Gerber LH, Younossi ZM

623 Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma
Mohamed GA, Nashaat EH, Fawzy HM, ElGhandour AM

Randomized Clinical Trial
634 Effect of a specific Escherichia coli Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment
Manzhalii E, Moyseyenko V, Kondratiuak V, Molochek N, Falalyeyeva T, Kobyliak N
ABOUT COVER
Editorial Board Member of World Journal of Hepatology, Rostyslav Bubnov, MD, PhD, LLB, Senior researcher in The Interferon Department of Zabolotny Institute of Microbiology and Virology, National Academy of Sciences of Ukraine; Medical doctor in The Center of Ultrasound Diagnostics and Interventional Sonography, Clinical Hospital “Pheophania” of Administration of President of Ukraine, Kyiv 03157, Ukraine. rostbubnov@gmail.com

AIMS AND SCOPE
The primary aim of World Journal of Hepatology (WJH, World J Hepatol) is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJH mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING
The WJH is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2021 edition of Journal Citation Reports® cites the 2020 Journal Citation Indicator (JCI) for WJH as 0.61. The WJH’s CiteScore for 2020 is 5.6 and Scopus CiteScore rank 2020: Hepatology is 24/62.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Rui-Rui Wu; Production Department Director: Xiang Li; Editorial Office Director: Xiang Li.

NAME OF JOURNAL
World Journal of Hepatology

ISSN
ISSN 1948-5182 (online)

LAUNCH DATE
October 31, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Nikolaos Pyrrooulos, Ke-Qin Hu, Koo Jeong Kang

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
March 27, 2022

COPYRIGHT
© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/278

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
MINIREVIEWS

New progress in understanding roles of nitric oxide during hepatic ischemia-reperfusion injury

Yi-Ping Zhang, Xin-Ran Liu, Mei-Wen Yang, Shu-Long Yang, Fen-Fang Hong

 Specialty type: Pharmacology and Pharmacy
 Peer-review model: Single blind
 Peer-review report’s scientific quality classification
 Grade A (Excellent): 0
 Grade B (Very good): 0
 Grade C (Good): C
 Grade D (Fair): D
 Grade E (Poor): 0
 P-Reviewer: Ramadan N, Serafini S
 Received: March 29, 2021
 Peer-review started: March 29, 2021
 First decision: June 15, 2021
 Revised: July 9, 2021
 Accepted: February 19, 2022
 Article in press: February 19, 2022
 Published online: March 27, 2022

Abstract

Hepatic ischemia-reperfusion injury (HIRI) is a major clinical cause of morbidity and mortality in liver surgery and transplantation. Many studies have found that nitric oxide (NO) plays an important role in the HIRI and its increase or decrease can affect the progression and outcome of HIRI. However, the role of NO in HIRI is controversial and complicated. NO derived by endothelial NO synthase (eNOS) shows a protective role in HIRI, while excessive NO derived by inducible NO synthase (iNOS) accelerates inflammation and increases oxidative stress, further aggravating HIRI. Nevertheless, the overexpression of eNOS may exacerbate HIRI and iNOS-derived NO in some cases reduces HIRI. Here we review the new progress in the understanding of the roles of NO during HIRI: (1) NO possesses different roles in HIRI by increasing NO bioavailability, down-regulating leukotriene C4 synthase, inhibiting the activation of the nuclear factorκB (NFκB) pathway, enhancing cell autophagy, and reducing inflammatory cytokines and reactive oxygen species (ROS). And NO has both protective and deleterious effects by regulating apoptotic factors; (2) eNOS promotes NO production and suppresses its own overexpression, exerting a hepatoprotective effect reversely. Its activation is regulated by the PI3K/Akt and KLF2/AMPK pathways; and (3) iNOS derived NO mainly has deteriorating effects on HIRI, while it may have a protective function under some conditions. Their expression should reach a balance to reduce the adverse side and make NO protective in the treatment of HIRI. Thus, it can be inferred that NO modulating drugs may be a new direction in the treatment of HIRI or may be used as an adjunct to mitigate HIRI for the
Hepatic ischemia-reperfusion injury (HIRI) is a major complication often seen in liver surgery and organ transplantation. It manifests as cellular damage during the ischemic phase and worsens during reperfusion. Depending on the different conditions of ischemia, HIRI can be divided into warm ischemia-reperfusion (WIR) injury and cold ischemia-reperfusion injury (IRI), which have similar pathophysiology but different clinical injury sites[1].

With a high incidence of cases, liver cancer has increased by 114.0% and ended up with 1007800 cases in 2016[2]. Many liver cancer patients are supposed to be treated by liver transplantation or hepatectomy, where HIRI occurs during the operation [3]. Although HIRI is receiving increasing attention to improve the success rate of surgery and improve prognosis, very few of them are known.

The pathophysiological process of hepatic IRI involves the interaction of many different cell types and numerous signaling pathways such as anaerobic metabolism, acidosis, oxidative stress, and intracellular calcium overload. Among the interactions, the imbalance in the ratio of endothelin (ET) to nitric oxide (NO) is one of the mechanisms involved in HIRI. Normally, their function is to regulate blood flow to the hepatic sinusoids. In contrast, in the first few hours after reperfusion, as ET rises, plasma expression of NO decreases, leading to an increase in the ET/NO ratio and the possible appearance of HIRI[4,5].

Many pieces of evidence show that NO plays an important role in ischemia-reperfusion (I/R) [6,7]. However, as a vasodilator, the role of NO has been controversially discussed by scientists[8,9]. In past studies, NO was regarded as a negative factor because of its cytotoxic effect[10]. Nevertheless, a recent study indicated that NO can induce either a positive or negative effect during the early phase of HIRI and have a protective effect during late HIRI[11]. Therefore, it is important to further explore the protective mechanism of NO in HIRI.

NO is a small molecule free radical that can easily penetrate cell membranes. It is also an important effector and messenger molecule of biological information, which has undergone many extensive types of research in the past few years. There are two sources of NO in the human body—enzymatic production and non-enzymatic production. Non-enzymatic production mainly comes from chemical degradation and inorganic nitrogen transformation on the body surface or ingested. For enzymatic production, NO is oxidized from L-arginine by NO synthase (NOS)[12].

There are Ca²⁺-independent and Ca²⁺-dependent NOS in the human body. Ca²⁺-dependent NOS can be subdivided into neuronal (nNOS) and endothelial (eNOS). eNOS is an enzyme continuously expressed in vascular endothelial cells and exerts biological functions through producing NO. In contrast to eNOS, Ca²⁺-independent inducible NOS (iNOS) is activated by some exterior factors including viruses, bacteria, pro-inflammatory interferon, and cytokines[13]. iNOS produces a large amount of NO in hepatocytes, cholangiocytes, and Kupffer cells (KCs), helping macrophages to mount an immune response[14].

**Key Words:** Hepatic ischemia-reperfusion injury; Nitric oxide; Endothelial nitric oxide synthase; Inducible nitric oxide synthase

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhang YP, Liu XR, Yang MW, Yang SL, Hong FF. New progress in understanding roles of nitric oxide during hepatic ischemia-reperfusion injury. World J Hepatol 2022; 14(3): 504-515

**URL:** https://www.wjgnet.com/1948-5182/full/v14/i3/504.htm

**DOI:** https://dx.doi.org/10.4254/wjh.v14.i3.504

**INTRODUCTION**

Hepatic ischemia-reperfusion injury (HIRI) is a major complication often seen in liver surgery and organ transplantation. It manifests as cellular damage during the ischemic phase and worsens during reperfusion. Depending on the different conditions of ischemia, HIRI can be divided into warm ischemia-reperfusion (WIR) injury and cold ischemia-reperfusion injury (IRI), which have similar pathophysiology but different clinical injury sites[1].

With a high incidence of cases, liver cancer has increased by 114.0% and ended up with 1007800 cases in 2016[2]. Many liver cancer patients are supposed to be treated by liver transplantation or hepatectomy, where HIRI occurs during the operation [3]. Although HIRI is receiving increasing attention to improve the success rate of surgery and improve prognosis, very few of them are known.

The pathophysiological process of hepatic IRI involves the interaction of many different cell types and numerous signaling pathways such as anaerobic metabolism, acidosis, oxidative stress, and intracellular calcium overload. Among the interactions, the imbalance in the ratio of endothelin (ET) to nitric oxide (NO) is one of the mechanisms involved in HIRI. Normally, their function is to regulate blood flow to the hepatic sinusoids. In contrast, in the first few hours after reperfusion, as ET rises, plasma expression of NO decreases, leading to an increase in the ET/NO ratio and the possible appearance of HIRI[4,5].

Many pieces of evidence show that NO plays an important role in ischemia-reperfusion (I/R) [6,7]. However, as a vasodilator, the role of NO has been controversially discussed by scientists[8,9]. In past studies, NO was regarded as a negative factor because of its cytotoxic effect[10]. Nevertheless, a recent study indicated that NO can induce either a positive or negative effect during the early phase of HIRI and have a protective effect during late HIRI[11]. Therefore, it is important to further explore the protective mechanism of NO in HIRI.

NO is a small molecule free radical that can easily penetrate cell membranes. It is also an important effector and messenger molecule of biological information, which has undergone many extensive types of research in the past few years. There are two sources of NO in the human body—enzymatic production and non-enzymatic production. Non-enzymatic production mainly comes from chemical degradation and inorganic nitrogen transformation on the body surface or ingested. For enzymatic production, NO is oxidized from L-arginine by NO synthase (NOS)[12].

There are Ca²⁺-independent and Ca²⁺-dependent NOS in the human body. Ca²⁺-dependent NOS can be subdivided into neuronal (nNOS) and endothelial (eNOS). eNOS is an enzyme continuously expressed in vascular endothelial cells and exerts biological functions through producing NO. In contrast to eNOS, Ca²⁺-independent inducible NOS (iNOS) is activated by some exterior factors including viruses, bacteria, pro-inflammatory interferon, and cytokines[13]. iNOS produces a large amount of NO in hepatocytes, cholangiocytes, and Kupffer cells (KCs), helping macrophages to mount an immune response[14].
eNOS and iNOS are believed to take actions in HIRI. While depending on different isoforms of NOS, NO has a dual effect on hepatocellular functions during IR. eNOS-derived NO is hepatoprotective of ischemia following IRI by improving hepatic microcirculation and counteracting the deteriorate functions of reactive oxygen species (ROS) [4]. However, an augmented level of iNOS activation upon reperfusion will produce excessive NO, resulting in endothelial dysfunction and aggravating liver damage in HIRI[14]. It has been reported that iNOS-derived NO may have a positive or negative function in HIRI depending on the different conditions[15].

This review aims to find the role of NO during HIRI and look for candidate ways to alleviate liver damage (Table 1).

**DIFFERENT ROLES OF NO DURING HIRI**

Recently, studies have showed that NO has a significant role during the HIRI, which can be a protective function or negative deleterious function. NO was proved to reduce HIRI through various mechanisms such as increasing NO bioavailability, down-regulating leukotrienes (LTs), inhibiting liver cell apoptosis, enhancing autophagic flux, maintaining liver microcirculation blood flow, stabilizing ATP levels, and reducing oxidative stress injury. Whereas, NO can also regulate some apoptotic signal pathways to accelerate the apoptosis of hepatic tissue.

**Increase of NO bioavailability involved in its protective effect in HIRI**

Hide D et al[16] found that NO bioavailability was reduced during reperfusion by detecting the levels of cyclic guanosine monophosphate, a second messenger of NO. They concluded that the decreased NO bioavailability can be explained by the reduction of eNOS activity leading to less synthesis of NO and increased NO clearance by reacting with ROS and forming peroxynitrite, which may later react with cell components such as proteins, lipids, and DNA, further damaging the cell. Therefore, increasing NO bioavailability can protect the liver from further damage during HIRI. It is reported that obestatin enhances NO bioavailability by up-regulating eNOS expression[17]. Also, simvastatin maintains NO bioavailability by preventing kruppel-like factor 2 (KLF2) down-regulation[16].

**NO can down-regulate LTC4S by inhibiting the nuclear factor kappαB pathway**

Many studies reveal that cysteinyl leukotrienes are directly associated with hepatic IRI. Leukotriene C4 synthase (LTC4S) is one of the enzymes that are responsible for LTC4 synthesis, showing a strong relationship with the NO[18,19]. In I/R rats, the gene expression level of LTC4S is much higher. However, this is reversed by V-PYRRO/NO, which acts as an NO donor. Hong FF et al[20] also found that another NO donor, sodium nitroprusside, could down-regulate the mRNA expression of LTC4S by inhibiting nuclear factor-kappa B (NF-κB) activation in an NF-κB inhibitor-independent manner by detecting the protein levels of NF-κB p65 and p50 in the nuclear extracts using Western Blot.

**NO can regulate some apoptotic signal transduction pathways and factors**

NO has a significant role in regulating some apoptotic signal transduction pathways which can be potentially activated to induce or inhibit the hepatic cell apoptosis process caused by HIRI during the hepatic operation or other hepatic diseases. The signal pathways or apoptosis-related genes including caspasases[21-25], Bcl-2 gene family[26-30], mitogen-activated protein kinase (MAPK)[31], and NF-kB[32]. Studies have shown that the caspase family is strongly related to hepatic cell apoptosis[33]. Zhao P et al [21] found that steatosis-induced decline in adenosine monophosphate-activated protein kinase (AMPK)-catalyzed phosphorylation permits caspase-6 activation, leading to hepatocyte death. And Gao D et al[22] indicated that caspase-3A is involved in cadmium (Cd)-induced cell apoptosis in common carp, which showed 71.8% sequence similarity and 59.3% sequence identity to human caspase-3. Zhang R et al[23] found that Cd treatment increased the level of iNOS and NO. The overexpression of NO leads to chicken hepatic cell apoptosis by inducing the mitochondrial apoptotic pathway. In two other studies, mouse liver cell apoptosis can be inhibited by reducing NO content, down-regulating Bax protein expression, and increasing Bcl-2 protein expression[24,25]. Besides, an imbalanced Bax/Bcl-2 ratio is caused by decreasing levels of NO and iNOS and increasing Bcl-2 expression through the NF-kB pathway. And this imbalanced ratio may show a protective role in the damaged liver[30]. Jiang Q et al [34] also found that 7-mer peptide can increase the level of Bcl-2 and decrease the level of Bax expression to reduce apoptosis and protect against IRI.

**NO protects against I/R-induced liver injury by enhancing autophagic flux**

NO has an important role in protecting against I/R-induced liver injury by enhancing autophagic flux. During severe environments such as IRI, the cell will undergo an autophagic process, which is an adaptive response to reduce the injury. Studies have found that the protective mechanism of NO during HIRI is associated with autophagic flux. Shin JK et al[35] demonstrated that NO could enhance light chain-3 lipidation and autophagosome-lysosome fusion during hepatic I/R. Also, eNOS-induced NO enhances autophagy via p38 MAPK activation during liver I/R. Simvastatin, which is used to protect the
Table 1 Roles of nitric oxide, inducible nitric oxide synthase, and endothelial nitric oxide synthase in various conditions and pharmacological protection against hepatic ischemia-reperfusion injury

<table>
<thead>
<tr>
<th>Pretreatment</th>
<th>NO/ iNOS/ eNOS levels</th>
<th>Animals</th>
<th>Experimental cells</th>
<th>Mechanism</th>
<th>Liver cell necrosis and liver damage</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>NMP, BMSCs, and liver CDC</td>
<td>eNOS†, iNOS↓</td>
<td>SPF rats</td>
<td>Liver tissue</td>
<td>Macrophage activation, ICAM-1, VCAM-1, vWF↓</td>
<td>↓</td>
<td>[5]</td>
</tr>
<tr>
<td>L-NAME and BDL</td>
<td>iNOS mRNA↓</td>
<td>Male Wistar rats</td>
<td>Liver tissue</td>
<td>TGF-β, NOx, HA; AMDA↑</td>
<td>↓</td>
<td>[6]</td>
</tr>
<tr>
<td>Simvastatin and WIR</td>
<td>NO†</td>
<td>Male Wistar rats</td>
<td>Primary LSEC</td>
<td>Nitrotyrosines, O2−↓; Nrf2, HO-1↑</td>
<td>↓</td>
<td>[14]</td>
</tr>
<tr>
<td>Simvastatin and WIR</td>
<td>NO, eNOS†</td>
<td>Male Wistar rats</td>
<td>LSEC</td>
<td>KLF2, p-eNOS, cGMP†; O2−, VCAM-1↓</td>
<td>↓</td>
<td>[16]</td>
</tr>
<tr>
<td>Obestatin and HIRI</td>
<td>eNOS†, iNOS↓</td>
<td>Adult Wistar albino male rats</td>
<td>Liver tissue samples</td>
<td>Reducing oxidative stress and inflammatory process</td>
<td>↓</td>
<td>[17]</td>
</tr>
<tr>
<td>HIRI</td>
<td>NO†</td>
<td>Male Sprague-Dawley rats</td>
<td>Liver</td>
<td>Decrease synthesis of LTC4S, NF-κB</td>
<td>↓</td>
<td>[18,19]</td>
</tr>
<tr>
<td>V-PYRRO/NO and HIRI</td>
<td>NO†</td>
<td>Male Sprague-Dawley rats</td>
<td>Liver</td>
<td>Decrease synthesis of LTC4S, NF-κB</td>
<td>↓</td>
<td>[19]</td>
</tr>
<tr>
<td>AMPK-caspase-6 axis and nonalcoholic steatohepatitis</td>
<td>-</td>
<td>LAKO mice</td>
<td>Hepatocyte</td>
<td>Caspases-6 activation</td>
<td>↓</td>
<td>[21]</td>
</tr>
<tr>
<td>Cd-Induced Apoptosis</td>
<td>NO†, iNOS†</td>
<td>Hy-Line Brown laying hen</td>
<td>Liver</td>
<td>Mitochondrial apoptotic pathway</td>
<td>↓</td>
<td>[22]</td>
</tr>
<tr>
<td>Punicalagin and cyclophosphamide</td>
<td>NO, iNOS↓</td>
<td>Sprague-Dawley male rats</td>
<td>Liver</td>
<td>Reduce cell apoptosis</td>
<td>↓</td>
<td>[25]</td>
</tr>
<tr>
<td>Emblica offcinalisGaertn and NAP</td>
<td>NO↓</td>
<td>Male Wistar rats</td>
<td>Liver</td>
<td>Apoptosis, autophagy, inflammation↓</td>
<td>↓</td>
<td>[28]</td>
</tr>
<tr>
<td>Tormentic acid and LPS/ D-GalN</td>
<td>NO, iNOS↓</td>
<td>Male C57BL/6 mice</td>
<td>Liver samples</td>
<td>TNF-α, NF-κB↓; imbalanced Bax/Bcl-2 ratio</td>
<td>↓</td>
<td>[30]</td>
</tr>
<tr>
<td>Selenocysteine-containing 7-mer peptide</td>
<td>NO↓</td>
<td>Adult male Wistar rats</td>
<td>Liver tissue</td>
<td>Inhibit oxidant peroxynitrite, Bax↓; Bcl-2↑</td>
<td>↓</td>
<td>[34]</td>
</tr>
<tr>
<td>IPC and HIRI</td>
<td>NO†</td>
<td>Male C57BL/6 mice</td>
<td>Liver tissue</td>
<td>p38 MAPK↓; autophagy↑</td>
<td>↓</td>
<td>[35]</td>
</tr>
<tr>
<td>Simvastatin and hepatic transplantation</td>
<td>NO†</td>
<td>Male rats</td>
<td>Liver</td>
<td>Autophagy↑</td>
<td>↓</td>
<td>[36]</td>
</tr>
<tr>
<td>IPC</td>
<td>NO†</td>
<td>Male Sprague-Dawley rats</td>
<td>Liver</td>
<td>Oxygen species liberation and proinflammatory cytokine; microcirculation↑</td>
<td>↓</td>
<td>[37]</td>
</tr>
<tr>
<td>Oxytocin and HIRI</td>
<td>NO†</td>
<td>Adult male albino (Sprague Dawley strain)</td>
<td>Liver</td>
<td>NO bioavailability↑</td>
<td>↓</td>
<td>[38]</td>
</tr>
<tr>
<td>TELL and HIRI</td>
<td>eNOS†</td>
<td>Male Wistar rats</td>
<td>Liver</td>
<td>Activate PI3K/Akt pathway, suppress TLR4, p-Pi3K, p-Akt, Nrf2, p-NF-kB p65, p-MAPK p38, TNF-α, GSH, MyD88, HMGB-1, TBARS↓; NF-kB↑</td>
<td>↓</td>
<td>[42]</td>
</tr>
<tr>
<td>Apelin preconditioning and HIRI</td>
<td>eNOS†</td>
<td>Male albino rats</td>
<td>Liver tissue</td>
<td>Activate PI3K/Akt pathway, suppress ATIR, counteract Ang II/AT1R system</td>
<td>↓</td>
<td>[43]</td>
</tr>
<tr>
<td>Simvastatin and WIR</td>
<td>eNOS†</td>
<td>Male inbred Sprague Dawley rats</td>
<td>Liver tissue</td>
<td>Activate KLF2 pathway, TM, p-eNOS†, TGF-β, TNF-α, IL-1β↓</td>
<td>↓</td>
<td>[44]</td>
</tr>
<tr>
<td>HMP and liver DCD</td>
<td>NO, eNOS†</td>
<td>Adult male Sprague-Dawley rat</td>
<td>Liver</td>
<td>KLF2↑; NF-kB p65, IL-1β, TNF-α↓</td>
<td>↓</td>
<td>[45]</td>
</tr>
<tr>
<td>TMZ and WIR</td>
<td>eNOS†</td>
<td>Male Wistar rats</td>
<td>Liver tissue</td>
<td>p-MAPK↑; activate MAPK pathway</td>
<td>↓</td>
<td>[46]</td>
</tr>
</tbody>
</table>
Zhang YP et al. Nitric oxide action on HIRI

IGL-1 and Fatty Liver
Graft Cold Storage

| eNOS† | Homozygous (obese) | Liver | Activate MAPK pathway, ATP† | ↓ | [48] |
| SEW2671 and WIR | eNOS† | Male C57BL/6 mice | SECs | VE-cadherin, p-Akt† | ↓ | [49] |
| EPO and liver transplantation | eNOS† | Female landrace pigs | Liver tissue | Activate JAK2/P38/PI3K pathway, AMPK†, βcR2-VEGFR-2 complex | ↓ | [51] |
| HIRI | - | Female domestic (Landrace) pigs | Liver tissue | IL-6, STAT-3 and E-selectin mRNA† | - | [52] |
| TDF and HIRI | eNOS, iNOS↓ | Female Wistar albino rats | Liver tissue | cGMP+, activate mitochondrial K-ATP channels, mitochondrial Ca2+↓ | ↓ | [53] |
| PTX and HIRI | eNOS, iNOS↓ | Male Wistar rats | Liver | TNF-α, NF-κB, Bcl-2↓ | ↑ | [54] |
| L-Arginine/CDN and HIRI | NO, eNOS†, iNOS↓ | Male Wistar rats | Liver | TNF-α, NF-κB↓, Bcl-2↓ | ↓ | [55] |
| iNOS knockout and WIR | iNOS↑ | C57BL/6 male rats | 293 T cells | PUMA↑ | ↑ | [56] |
| NAC and HIRI | eNOS↑, iNOS↓ | Male Wister albino rats | Liver | NOSTRIN, MDA, MAPK activity↓ | ↓ | [57] |
| TQ and HIRI | iNOS†, iNOS↑ | Male Wistar rats | Liver | NOSTRIN, MDA, oxidative stress, nitrosative stress↓, GSH↑ | ↑ | [58] |
| LA and HIRI | iNOS mRNA↑ | Male Wistar rats | Liver | NF-κB p65, MIP-2 mRNA, GSH↑ | ↓ | [59] |
| V and HIRI | NO, iNOS mRNA↑ | Male Wistar rats | Lung and Liver tissue | Inhibit HIF-α/HGF/iNOS pathway | ↓ | [60] |
| Eupatilin and HIRI | iNOS↑ | Male C57BL/6 mice | Embryonic liver BNL CL.2 cell | TLR2/4, p-IκBα, Bcl-2↑ | ↑ | [61] |
| N-SMase inhibitor and HIRI | iNOS↑ | Male Wistar rats | Liver tissue | Protein nitration, nitrite/nitrate levels, HNE↑ | ↓ | [62] |
| Ad-eNOS and small-for-size liver transplantation | NO, eNOS† | - | Human normal liver cell line L02 | TNF-α↓, inhibit macrophage activation | ↑ | [63] |
| Ad-eNOS and HIRI | eNOS† | Male inbred C57BL6 lean mice | Liver | ATP↓, bax, p53↑ | ↓ | [64] |

L-NAME: Nomega-nitro-L-arginine methyl ester; BDL: Bile duct ligation; WIR: Warm ischemia and reperfusion; LSEC: Rat liver sinusoidal endothelial cells; KLF2: Kruppel-like factor 2; VEGAM: Vascular endothelial cell adhesion molecule-1; HIRI: Hepatic ischemia reperfusion injury; NF-κB: nuclear factor-kappaB; LTC4S: Leukotriene C4 synthase; AMPK: Adenosine monophosphate activated protein kinase; IFN: Interferon; TNF: Tumor necrosis factor-α; ICAM-1: Intracellular cell adhesion molecule-1; Thymoquinone; Ad-eNOS: Adenovirus-eNOS; N-SMase: Neutral sphingomyelinase; HNE: 4-hydroxynonenal; VEGFR: Vascular endothelial growth factor receptor; ICAM-1: Intracellular cell adhesion molecule-1; βcR: Common β receptor; NOSTRIN: Nitric oxide synthase trafficking.

NO decreases inflammatory cytokines and ROS by inhibiting the mitochondrial respiratory chain

During reperfusion, the surge of inflammatory factors, cytokine liberation, neutrophil infiltration and ROS generation occurred, which led to hepatic injury. An increased level of NO can reduce cytokines such as tumor necrosis factor-α (TNF-α) and interleukin (IL)-1 which stimulate infiltration and donor liver, can activate autophagy and increase NO release during hepatic transplantation. This also indicates the possible connection between NO and autophagy[36].

endothelial injury. Also, continuous NO production can reduce ROS and proinflammatory cytokine generation as well as neutrophil infiltration[37]. Inversely, NO deficiency can induce TNF-α expression as a result of ROS surging. Ragy MM et al[38] proved this by adding Nomega-nitro-L-arginine methyl ester (L-NAME) in IRI model rats treated with oxytocin. In this group, not only did the parameter damage increase but also the inflammatory factor such as TNF-α level increased compared with the control group.

ROLE OF ENOS IN HIRI
Activated eNOS produces NO to protect HIRI
eNOS performs various biological functions by promoting the production of NO, which is important for maintaining vascular tone and cardiovascular hemostasis, and inhibiting platelet activation and aggregation. It has been confessed that eNOS shows a hepatoprotective effect in HIRI by improving the production of NO(Figure 1).

There are two main regulation pathways for eNOS activation, one dependent on intracellular concentration of Ca2+ and the other independent. The increasing intracellular Ca2+ level can enhance the affinity of calmodulin binding to eNOS and activate enzymes to produce NO[39]. For the Ca2+-independent regulation pathway, phosphorylation of the Ser1177 residue or dephosphorylation of the Thr495 residue activates it to produce NO[40].

Calcium-dependent eNOS activation
At the early stage of HIRI, the ischemia will lead to a shortage of oxygen and nutrients, which can decrease ATP availability. Without energy, ATP-dependent ion channels or transporters cannot work. The incompetence of the Na+/K+ pump leads to depolarization of the cell membrane, resulting in the influx of Ca2+[41]. Besides, anaerobic glycolysis induces an increase in H+, which activates intracellular proteases to increase cellular permeability. Furthermore, Na+/Ca2+ exchange is activated due to a high concentration of H+, leading to a further influx of Ca2+. Consequently, eNOS is activated due to the increase of intracellular concentration to produce NO, carrying anti-HIRI activities at the initial stage.

Calcium-independent eNOS activation
Phosphoinositide 3-kinase/Akt pathway induced eNOS activation: The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is a cell survival pathway that regulates cell proliferation and apoptosis, as well as an endogenous negative feedback regulator that functions in anti-inflammation and anti-apoptosis effects in IR.

PI3K can activate Akt to act on the phosphorylation of eNOS. It has been proven that telluric acid has a hepatoprotective effect by elevating the expression of eNOS, which is accompanied with elevated expression of p-PI3K and p-Akt proteins. Besides, the activation of PI3K/Akt also inhibits NF-kB and activates nuclear erythroid-related factor-2, reducing pro-inflammation cytokine expression and inducing anti-oxidative effects[42]. Moreover, through the PI3K/Akt pathway, apelin preconditioning can increase the expression of eNOS and counteract the pathological effects of the angiotensin II/angiotensin II type 1 receptor system in HIRI[43]. Thus, the activation of the PI3K/Akt pathway leads to the phosphorylation of eNOS and continuous catalysation of NO production, which is essential to counteract HIRI.

KLF2 induced eNOS activation: There may exist other ways of influencing the eNOS activity during IR. It has been proven that WIR injury can decrease the expression of KLF2 in endothelial cells. Also, this reduction is accompanied by a decrease in phosphorylated eNOS (p-eNOS), one of the KLF2 targets. And the IR damage can be mitigated by pretreatment with simvastatin through a KLF2-dependent mechanism, upregulating the mRNA expression of KLF2 and eNOS as well as the protein expression of KLF2 and p-eNOS[16,44]. Hu X et al[45] also demonstrated that hypothermic machine perfusion inhibited NF-kB signaling and activated eNOS/NO signaling through KLF2 expression, thereby alleviating the inflammatory response and oxidative stress injury. It has demonstrated that KLF2 activators can be candidate therapeutic agents for HIRI.

AMPK induced eNOS activation: AMPK plays a key role in the regulation of cellular energy homeostasis. The activation of this kinase is a response to the stimulus. Mahfoudh Boussaid A et al[46] reported that repeated administration of trimetazidine protected against WIR injury by decreasing liver damage and oxidative stress. The underlying mechanism involves the activation of the AMPK/eNOS signaling pathway. In addition, similar mechanisms have been identified in the protective effect of Institut Georges Lopez 1 solution on cold-stored fatty liver grafts. The effect is mainly exerted through the activation of the AMPK pathway, which targets eNOS to produce NO, offsetting aggravated microcirculatory changes, and improving vascular resistance and function during IR[47,48].

Other pathways: SEW2871, a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, can restore
Figure 1 Hepatoprotective effects of endothelial nitric oxide synthase-derived nitric oxide during hepatic ischemia-reperfusion injury and underlying mechanisms. Nrf2: Nuclear erythroid-related factor; HO-1: Heme oxygenase-1; IL-1: Interleukin-1; TNF-α: Tumor necrosis factor-α; NF-κB: Nuclear factor-κ-gene binding; LTC4: Leukotriene C4; GSH: Glutathione; COX-2: Cyclooxygenase 2; ROS: Reactive oxygen species; ICAM-1: Intracellular cell adhesion molecule-1; AMPK: Adenosine monophosphate activated protein kinase; MAPK: Mitogen-activated protein kinase; iNOS: Inducible nitric oxide synthase.

The expression of eNOS and vascular endothelial (VE) cadherin in sinusoidal endothelial cells during HIRI in vivo and does not influence the expression of p-Akt. Thus, there may be a regulation pathway between S1PR1 and eNOS[49]. And the expression of VE-cadherin is important for vascular integrity, which is the basis for eNOS expression[49].

Moreover, ischemia preconditioning (IPC) can protect HIRI through p38 MAPK activation, which induces eNOS-derived NO expression to enhance cell autophagy in HIRI[35]. However, pretreatment with 3,7-dimethyl-1-propargylxanthine, an adenosine A2 receptor (A2AR) antagonist, can repeal the protective effect induced by IPC. Therefore, it can be inferred that there may be a relationship between the A2AR and eNOS[50].

The study of Kebschull L et al[51] showed that low-dose erythropoietin (EPO) treatment significantly increased hepatic NO bioavailability by up-regulating eNOS expression. EPO-mediated eNOS phosphorylation is promoted by EPOR-mediated activation of the Janus kinase 2/PI3K/Akt pathway and common β receptor (βcR)-dependent activation of AMPK. In addition to this, activation of the βcR2-vascular endothelial growth factor receptor-2 complex is also involved in the regulation, but its downstream signaling is currently unclear.

**ROLE OF INOS IN HIRI**

As mentioned above, iNOS-derived NO may have different functions in HIRI[15]. Although in most cases iNOS is considered to be harmful to the HIRI, it does not affect or even protects the HIRI in some conditions. In a study of models with liver ischemia and partial liver resection, iNOS mRNA expression was not found to be significantly altered compared to the sham group. While during 6 to 8 h after heptectomy, iNOS expression and NO production were promoted by cytokines, thereby improving liver microcirculation and preventing cell apoptosis[52]. The protective effect of iNOS has only been demonstrated in a few specific experiments and lacks widespread validation. Due to differences in experimental subjects, measurement criteria, and experimental time constraints, iNOS-derived NO exhibits a more complex and unclear role than eNOS.

**iNOS aggravates HIRI**

Hide D et al[14] found a surge of NO in WIR in aged livers, which was mainly induced by iNOS.
production. The surge of NO derived from iNOS can increase the expression of reactive nitrogen species (RNS) and inflammatory cytokines, resulting in cytotoxic damage in hepatocytes. Besides, the damage from iNOS is also confirmed in other studies. As intrahepatic macrophages, KCs are activated in early IRI, producing excessive amounts of iNOS-derived NO and leading to massive production of pro-inflammatory factors, cytokines, and ROS, which are key links to impaired microcirculation in the liver and deteriorate HIRI[5,33].

At the late phase of HIRI, the function of iNOS will be at a prominent stage. Excess NO derived from iNOS has cytotoxic effects that induce inflammation and excessive oxidation, and performs many deleterious functions in HIRI. Increased iNOS expression is associated with increased TNF-α and NF-κB, which leads to increased expression of pro-inflammatory genes, inflammatory mediators, and regulatory enzymes[54]. They are both important to trigger inflammation reactions and may have deleterious effects on IRI. Besides, in studying the role of iNOS/NO in the interferon regulatory factor-1 (IRF1) signaling pathway of primary human hepatocytes, Du Q et al[55] found the existence of a positive-feedback loop between iNOS and IRF1. The IRF1 and p53 can upregulate the p53 up-regulated modulator of apoptosis (PUMA), which is a modulator of apoptosis, resulting in hepatocyte death and further damage to hepatic IRI.

**REGULATING INOS AND ENOS EXPRESSION TO PROTECT HIRI**

The extent and intensity of eNOS and iNOS in HIRI are both higher than those in the normal state, while excess NO will produce peroxynitrite to aggravate IR damage. These can be reduced by using high doses of tadalafil and pentoxifylline to mitigate the deterioration of nitrosative stress and endothelial cell injury[53].

Iwasaki J et al[6] demonstrated that L-NAME, an NOS inhibitor, attenuated liver damage in IRI of cholestatic livers by inhibiting the NO production. Comparing the expression of iNOS and eNOS with L-NAME treatment, they found that this kind of protection was mainly mediated by the inhibitory effects of iNOS. It also prevented the increase of asymmetric dimethylarginine, which is an exogenous inhibitor of eNOS, to protect against IRI at the early stage.

Bone marrow mesenchymal stem cell (BMMSC) transplantation can regulate NOS synthesis by increasing eNOS expression as well as inhibiting iNOS expression and excessive NO production to protect HIRI and reduce hepatocyte apoptosis. Its regulations are closely related to the inhibition of NOS-induced macrophage activation, the suppression of large amounts of iNOS and NO synthesized by macrophages, and the amelioration of endothelial damage. And the combined use of BMMSCs and normothermic machine perfusion can increase the balance of ET/NO ratio[5].

Besides, the eNOS traffic inducer (NOSTRIN) can significantly inhibit NO release by decreasing the enzymatic activity of eNOS. Pretreatment with N-acetylcysteine or thymoquinone can up-regulate eNOS along with NO production and down-regulate iNOS and NOSTRIN expression to attenuate HIRI injury, showing the protective effect of increasing eNOS and NO levels and inhibiting iNOS expression against IRI in rat liver[36].

**Inhibiting iNOS to protect HIRI**

After reperfusion, the expression of inflammatory factors such as macrophage inflammatory protein-2 and iNOS increase with the activation of NF-κB, leading to a series of inflammation reactions. Alpha-lipoic acid can reduce the formation of excess NO during reperfusion by decreasing the expression of iNOS mRNA and reduce cellular damage from NO-forming NO superoxide and peroxide anions[57]. Beyond that, in a study of vildagliptin function in lung injury after hepatic IRI, significant inhibition of iNOS mRNA expression and NO was observed by the involvement of the hypoxia-inducible factor (HIF)-α/hepatocyte growth factor/iNOS pathway. The evaluated HIF-α can increase iNOS expression in various models. Therefore, targeting HIF-α expression can reduce tissue damage[58]. Furthermore, hepatic IR-induced iNOS protein expression can be diminished by eupatilin, which also suppresses the Toll-like receptor 2/NF-κB pathway to ameliorate inflammation response[59]. In addition, neural-sphingomyelinase (N-SMase) can produce ceramide, which is a mediator of iNOS expression. Inhibition of N-SMase leads to a decrease in iNOS levels, along with a decrease in protein nitrification and nitrate/nitrite levels in WIR[60].

**Inhibiting overexpression of and eNOS**

Some studies have demonstrated the hepatoprotective effect of genetic eNOS overexpression in small-for-size liver transplantation and illustrated the importance of promoting eNOS expression for hepatoprotection[61]. However, there is insufficient evidence for a protective effect of eNOS overexpression, and evidence that eNOS overexpression is detrimental to HIRI[62]. The dual effect of eNOS in HIRI remains controversial.

The fact is that the expression of eNOS will be deteriorated by oxidative stress and endothelial damage during the progression of ischemia, while the function of iNOS will be stimulated by oxidative stress during reperfusion and aggravate the liver injury. The imbalance of eNOS and iNOS can also
aggravate IRI.

**THERAPEUTIC PERSPECTIVES**

NOS drugs as well as drugs for the regulation of NOS enzymes may be the way forward for liver protection. However, more in-depth studies are still needed. Not only do drugs need to be stable, but they also need to avoid the harm that NO and NOS can cause to reduce side effects. Besides, despite a number of experimental studies demonstrating the beneficial effects of NO-releasing compounds and some drugs that promote NO release in ameliorating hepatic IRI, the results of trials and evaluations in the clinical setting are still lacking. Perhaps more randomised controlled clinical trials should be strengthened in the future to obtain more therapeutic results.

In a nutshell, increasing or decreasing NO availability in the hepatic tissue may both be ways to prevent and treat HIRI and identifying ways to balance the expression of eNOS and iNOS is important to protect IR and can be a promising direction for clinical research.

**CONCLUSION**

In general, NO along with eNOS and iNOS can play complex roles in HIRI. NO can down-regulate LTC4S by inhibiting the NFκB pathway, inhibit apoptotic related genes such as Bax and Bcl-2, enhance autophagic flux, decrease inflammatory cytokines, and reduce ROS by inhibiting the mitochondrial respiratory chain. Furthermore, NO induced by different NOS results in a duality of action in HIRI. NO derived by eNOS prefers to protect endothelial cells and attenuate liver injury in HIRI. However, iNOS promotes the production of NO in response to stimuli, thus exacerbating liver damage. But their role is not set in stone. Overexpression of eNOS also worsens HIRI, whereas iNOS has also been reported to have a protective effect against HIRI. Actually, these views remain controversial, and the underlying mechanisms are urgently needed to be clarified.

**FOOTNOTES**

**Author contributions:** Zhang YP and Liu XR are co-first authors and contributed equally to this work, and they wrote and revised the paper; Yang MW participated in data collection and revised the paper by making point-by-point responses to the reviewers; Yang SL and Hong FF are co-corresponding authors who contributed equally to this work, and they are responsible for improving grammars and languages, conceptualizing the idea, and obtaining funding.

**Conflict-of-interest statement:** There is no conflict of interest associated with any of the authors or other coauthors in this manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** China

**ORCID number:** Yi-Ping Zhang 0000-0003-4425-2165; Xin-Ran Liu 0000-0002-6050-2497; Mei-Wen Yang 0000-0002-8322-6181; Shu-Long Yang 0000-0002-1407-6255; Fen-Fang Hong 0000-0001-6440-1311.

**S-Editor:** Chang KL

**L-Editor:** Wang TQ

**P-Editor:** Chang KL

**REFERENCES**


Zhang YP

WJH

March 27, 2022

Volume 14

Issue 3

514

DOI: 10.1007/s11012-020-01917-w


Zhang YP et al. Nitric oxide action on HIRI


